2 results
Approved WMOCompleted
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
Approved WMOCompleted
The purpose of this study is to evaluate how safe telisotuzumab vedotin is and how telisotuzumab vedotin is tolerated as monotherapy and in combination with osimertinib.